Member Info for Sangijuelas1

The same thing happened twice last year. The first time it was disrupted because buying firepower was enough to beat them down mainly led by Richard Griffiths.
The second was the news of the Nasdaq listing, which increased interest and buying.

So unless there is news or you can get a buying consortium together it will carry on treading water.

It's not resistance. It's short algos controlling the price. Every time there's a flurry of buys they dump shares.

It's been going on for months.

.

Ophidian all LFT use in the EU has to be by professionals for the results to be recognised

Yeah Timster and I do.

This guy was claiming that he was only invested here through a managed pension fund.

Whether or not you are a bot you seem incredibly stupid. In your previous post you claimed your pension fund was invested here.

I don't think any pension fund invests in Aim stocks. Which one is it?

There are 2 things that are the main drivers in the SP going forward.

Sentiment in the pharma /microbiome sectors as a whole.
Results from trial data or sources of income

While the former is low the trial data would need to be pretty conclusive. We could have great readouts over the next 12 months but while sentiment is down they may not be so beneficial for the SP as they are not pivotal trials.

The bulk of my investment here is set on a 5 year time frame. I think the company is worth a lot of money. I am not expecting it to happen overnight as so many here are.

And also what have I said that was rampy? I just agreed with others that the financing was good news.

Get a grip

Have you got an example of one of these subtle negative posts. You really need to back up your libel with facts

Just because I am not a mindless ramper like many on here.

I have been in since 2018 and will probably still be in in 2025. That's why I know more about the company than so many here.

A trader would not have done so much research.

Stay Long
Show me 1 post where I have been negative on 4D

I have challenged moronic trader rampers
Those claiming that solely by listing on Nas there would be a rapid rerate to £5 a share

And I recently was critised for talking the share down because I said the 0518 data was not due at the end of June but maybe in Autumn

Just covid denier BS

Agreed Hopeingmore and for Nasdaq listing we needed a good CFO and no doubt the late John Beck was instrumental in getting this deal through his extensive industry contacts

So the additional cash may mean a rapid move into Phase 1B of the asthma trial explaining the additional sites in the US and Bradford or maybe the P3 Blautix trial in house rather than out-licensing?

Obviously not talking about selling entire holding at 92, just the 10% or so that I trade on the dips and spikes

You haven't been here long Biker, have you?

The rule is sell on news then buy the fall back, which I haven't done today as I was hoping for 92

Because when other companies approach Oxford for bespoke finance they could use 4D as the reference rate for their loan e. g. push for a lower rate on the basis of the info.

As you will see from info published on other deals there's no talk of the rate
https://www.businesswire.com/news/home/20210512005662/en/Oxford-Finance-Provides-125-Million-Credit-Facility-to-Kala-Pharmaceuticals

I also invest in an Aim company called Ideagen who can actually borrow from the likes of Santander. They don't tell you the interest rate either, the financial statement will just have an entry for the amount spent on debt.

Zaphod the interest rate would not be disclosed as it's commercially sensitive for the lender and 4D with regard to any future deals they each might negotiate

About Oxford Finance LLC
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $7 billion in loans, with lines of credit ranging from $5 million to $150 million. Oxford is headquartered in Alexandria, Va., with additional offices in San Diego, Calif.; Palo Alto, Calif.; and the greater Boston and New York City areas. For more information, visit
https://oxfordfinance.com/

Not really. They are not pivotal trials anyway. I prefer to look at the bigger picture

Yeah I started to worry but then my husband's girlfriend told me to get a grip so I did